Shopping Cart
Remove All
Your shopping cart is currently empty
CAY10726 is an arylurea fatty acid. It decreases ATP production by 28% in MDA-MB-231 breast cancer cells when used at a concentration of 10 μM. CAY10726 decreases proliferation and initiates apoptosis in MDA-MB-231 cells via depletion of the phospholipid cardiolipin and its precursor phosphatidylglycerol from the mitochondrial membrane.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | 35 days | 35 days | |
| 5 mg | $493 | 35 days | 35 days | |
| 10 mg | $862 | 35 days | 35 days | |
| 25 mg | $1,920 | 35 days | 35 days |
| Description | CAY10726 is an arylurea fatty acid. It decreases ATP production by 28% in MDA-MB-231 breast cancer cells when used at a concentration of 10 μM. CAY10726 decreases proliferation and initiates apoptosis in MDA-MB-231 cells via depletion of the phospholipid cardiolipin and its precursor phosphatidylglycerol from the mitochondrial membrane. |
| In vivo | In vivo, CAY10726 (2.5-40 mg/kg) reduces tumor volume and increases tumor cell apoptosis in a mouse MDA-MB-231 breast cancer xenograft model in a dose-dependent manner. |
| Synonyms | CAY10726 |
| Molecular Weight | 493 |
| Formula | C24H36ClF3N2O3 |
| Cas No. | 1611446-66-2 |
| Relative Density. | 1.176 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: 5 mg/mL (10.14 mM), Sonication is recommended. Ethanol: 12 mg/mL (24.34 mM), Sonication is recommended. DMF:PBS(pH7.2) (1:2): 0.33 mg/mL (0.67 mM), Sonication is recommended. DMF: 20 mg/mL (40.57 mM), Sonication is recommended. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.